Compare PD & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PD | EBS |
|---|---|---|
| Founded | 2009 | 1998 |
| Country | United States | United States |
| Employees | 1155 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 532.7M | 466.9M |
| IPO Year | 2019 | 2006 |
| Metric | PD | EBS |
|---|---|---|
| Price | $6.87 | $8.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 1 |
| Target Price | ★ $12.63 | $12.00 |
| AVG Volume (30 Days) | ★ 1.9M | 614.2K |
| Earning Date | 05-28-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 416.95 | 125.83 |
| EPS | ★ 1.87 | 0.07 |
| Revenue | $492,546,000.00 | ★ $742,900,000.00 |
| Revenue This Year | $3.58 | $1.29 |
| Revenue Next Year | $2.88 | N/A |
| P/E Ratio | ★ $3.74 | $116.79 |
| Revenue Growth | ★ 5.36 | N/A |
| 52 Week Low | $5.70 | $5.62 |
| 52 Week High | $17.45 | $14.06 |
| Indicator | PD | EBS |
|---|---|---|
| Relative Strength Index (RSI) | 51.16 | 43.90 |
| Support Level | $6.01 | $7.73 |
| Resistance Level | $7.91 | $8.95 |
| Average True Range (ATR) | 0.39 | 0.55 |
| MACD | -0.02 | -0.07 |
| Stochastic Oscillator | 37.55 | 27.17 |
PagerDuty Inc is a digital operations management platform that manages urgent and mission-critical work for a modern, digital business. Its PagerDuty Operations Cloud combines artificial intelligence (AI) operations (AIOps), automation, customer service operations, and incident management with a generative AI assistant to create a flexible, resilient, and scalable platform to protect revenue and improve customer experience, improve operational efficiency, and mitigate the risk of operational failures. The company generates revenue predominantly from cloud-hosted software subscription fees and term-license software subscription fees. Geographically, the company derives a majority of its revenue from the United States and the rest from International markets.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.